Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
12 oct. 2021 18h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
27 sept. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Sept. 27, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference
13 sept. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will...
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
30 août 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced...
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board
23 août 2021 10h18 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced...
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
20 juil. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
12 juil. 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
30 juin 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology
21 juin 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, June 21, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
14 juin 2021 14h53 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...